NCT00948142View on ClinicalTrials.gov

Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections

PHASE2CompletedINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Skin Diseases, Bacterial
Interventions
DRUG

CEM-102

600 mg BID oral tablets for 10-14 days

DRUG

Linezolid

600 mg BID oral tablets

DRUG

CEM-102

1500 mg BID oral tablets on Day 1 followed by 600 mg BID oral tablets for a total of 10-14 days

Trial Locations (16)

31406

Savannah

31904

Columbus

44304

Akron

48202

Detroit

59701

Butte

62701

Springfield

90015

Los Angeles

90501

Torrance

90509

Torrance

91105

Pasadena

91911

Chula Vista

91942

La Mesa

92056

Oceanside

92701

Santa Ana

93030

Oxnard

08244

Somers Point

Sponsors

Lead Sponsor

Arrevus Inc.
All Listed Sponsors
lead

Arrevus Inc.

INDUSTRY

NCT00948142 - Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections | Biotech Hunter | Biotech Hunter